HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $21
Benzinga Newsdesk 33 minutes ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $23 to $21.
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $23 to $21.